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1. Introduction   
Hepatitis A virus (HAV) is a member of the Hepatovirus genus of Picornaviridae family. HAV is 
a non-enveloped (naked), linear, single stranded RNA virus of an icosahedral symmetry 
measuring 27-32 nm in diameter (Feinstone, 1973). The infectious particle consists of capsid 
protein and RNA genome (Fig. 1). The buoyant density of the mature particle is 1.33g/cm3 in 
CsCl solutions and the sedimentation coefficient is 160S in sucrose solutions (Ticehurst, 1983).   
 
 
Fig. 1. The internal structure of hepatitis A virus showing capsid proteins and envelopes, 
structural region, single stranded RNA (open reading frame) and functional region.  
(Adapted from:  Anderson,1988) 
HAV causes an acute self limited illness. It does not lead to chronic hepatitis or a carrier 
state and only rarely leads to fulminant hepatic failure. HAV interferes with liver function 
and sparks an immune response that leads to liver inflammation (Koff, 1998). Natural 
infection with virus results from ingestion of fecally contaminated food and water. Virions 
apparently reach the liver through blood or systemic circulation and are taken up by 
hepatocytes (Siegl, 1988). The virus in the liver is recognized by receptor sites on the 
hepatocyte membrane and engulfed by the cell (Fig. 2) (Anderson, 1988). Inside the cell the 
virus uncoats, releases viral RNA and begins transcription (Teixeira, 1982). Once HAV 
completes replication in the liver, it excretes in bile and finally shed in stool.   
Like all picornaviral genomes, HAV is divided into three parts: (i) 5’ non-coding region 
(NCR) that comprises approximately 10% of the genome (ii) single open reading frame 
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(ORF) of 2227 amino acids, that encode all the viral proteins, with regions designated as P1 
for capsid proteins, P2 and P3 for non-structural proteins and (iii) short 3’ non-coding region 
(Fig. 3). HAV RNA genomes lack the cap assembly found at the 5’ end of mRNA species 
that normally guides the ribosomal complex to the translation start site (Najarian, 1985). 
Instead, an internal ribosome entry site (IRES) formed by the 5’NCR functions to initiate 
translations in HAV including other picornaviruses (Borman, 1997; Totsuka, 1999). 
However, unlike other picornavirus IRESes, the HAV IRES requires an intact eukaryotic 
initiation factor 4G for its optimal activity (Totsuka, 1999). Several other host proteins are 
found to be associated with synthetic RNAs representing segments of the 5’ NCR (Chang, 
1993). The viral capsid protein (P1) is further divided into VP4, VP2, VP3 and VP1 regions. 
The non-structural P2 and P3 polyproteins are divided into 2A, 2B, 2C and 3A, 3B, 3C, 3D 
respectively (Fig. 3). HAV polyprotein is processed into precursor intermediates and mature 
proteins by the proteolytic activities of encoded viral proteins. HAV 2A, 2B, 2C protein 
encodes 45, 251 and 335 amino acids respectively. The 2A and 3C are identified as 
 
 
Fig. 2. Diagrammatic representation of life cycle and replicative phase of hepatitis A virus. 
(Adapted from: Anderson, 1988) 
 
Fig. 3. Genomic structure of hepatitis A virus. HAV genome is divided into a 5’ non-coding 
region (5’ NCR), a giant open reading frame, and a non-coding region (3’ NCR). The coding 
region is subdivided into regions P1, P2 and P3. (Adapted from: Totsuka and Moritsugu, 1999) 
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processing enzyme in hepatitis A virus. The translated 2A regions function as intermediary, 
partially located on the surface (VP1) and some are assembled inside the virion (Totsuka, 
1999). Both 2B and 2C proteins play an important role in the replication of the viral RNA. P3 
polyproteins encodes 3A, 3B, 3C and 3D proteins with 74, 23, 219 and 489 amino acids 
respectively. 3C protein acts as sole protease for HAV protein processing, while 3D is the 
RNA dependent RNA polymerase (Schultheiss, 1994).   
2. Clinical and biochemical features 
Persistent infection of HAV takes four clinical phases. First phase is incubation period that 
varies from 15-45 days (mean 30 days) (Ciocca, 2000). HAV excretion in the faeces continued 
for 1-2 weeks before the onset of illness and at least 1 week afterward. The prodromal period 
corresponds to second phase and characterized by nonspecific symptoms followed by 
gastrointestinal symptoms such as nausea (loss of appetite), fatigue, abdominal pain, 
malaise, anorexia, fever, vomiting and flu like complaints (Lemon, 1997). These symptoms 
are usually short lived and followed by complete recovery. Third stage is mostly 
characterized by increase in bilirubin level. Jaundice becomes clinically apparent when the 
total bilirubin exceeds 2.0-4.0 mg/dL (Fig. 4). In half of the hepatitis A patients clinical signs 
such as hepatomegaly and hepatic tenderness are prominent. The final phase is a 
convalescent period during which the patient recovers. Signs and symptoms usually lasts 
for less than 2 months, although 10-15 percent of symptomatic persons have prolonged or 
relapsing illness lasting up to 6 months (Hussain, 2005). The increase of serum 
aminotransferases, bilirubin (both total and direct), and alkaline phosphatase is the most 
striking laboratory findings of hepatitis A. In most of the hepatitis A cases level of serum 
aminotransferases increases mildly, but in severe cases it may be elevated to significantly 
high level that ranges from 1,000-1,500 IU/liter (Hussain, 2005).  
2.1 Diagnostic features  
Hepatitis A cannot be differentiated from other types of viral hepatitis on the basis of 
clinical or epidemiologic features alone. Diagnosis of acute hepatitis A is based upon the 
detection of anti-HAV IgM antibodies or presence of HAV RNA in serum or faeces. In the 
majority of persons, serum anti-HAV IgM becomes detectable 5-10 days before onset of 
symptoms. IgM antibodies are detectable soon after infection and can remain detectable for 
about 6 months (Fig. 4). The anti-HAV IgG appears early in the course of infection and 
remain detectable for the person's lifetime and provides lifelong protection against the 
disease.  Total anti-HAV testing is used in epidemiologic studies to measure the prevalence 
of previous infection or by clinicians to determine whether a person with an indication for 
pre-exposure prophylaxis is already immune. HAV RNA can be detected in the blood and 
stool of the majority of persons during the acute phase of infection by using nucleic acid 
amplification methods, and sequencing is used to determine the relatedness of HAV isolates 
for epidemiologic investigations. HAV RNA can also be detected in blood during the 
incubation period, acute phase, and 18-30 days after the onset of illness (Kwon, 2000; 
Hussain, 2006). However recent study suggests presence of HAV RNA for an average of 95 
days and viremia persisted longer after the onsets of symptoms (average, 79 days) (Bower, 
2000; Normann, 2004). 
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Fig. 4. The serological course of hepatitis A virus. The virus can be detected in the feces up 
to 2 weeks before the appearance of the jaundice and up to 2 weeks afterwards. (Adapted 
from Lemon, 1997) 
3. Epidemiological characteristics  
Hepatitis A is an enterically transmitted viral infection of public health problem all over the 
world. Faecally contaminated food and water is the common source of HAV infection. 
Consumption of contaminated food is a leading cause of large number of outbreaks in the 
past that affect hundreds and thousands of people (Koff, 1998). The source of most reported 
foodborne hepatitis A outbreaks has been HAV-infected food handlers. Waterborne 
transmission predominates in developing countries and is responsible for infection at early 
age. Therefore, it is responsible for endemicity rather than clinical outbreaks. In contrast, 
waterborne transmission in developed countries accounts for a very small proportion of 
HAV infections. Ninety percent of infections in children are subclinical or asymptomatic 
whereas exposure of adults and adolescents mainly leads to clinical form. Asymptomatic or 
unrecognized infections in children play an important role in HAV transmission and serve 
as a primary source of infections to others. The special groups of adult population such as 
men who have sex with men (MSM) or intravenous drug users (IVDUs) sustained the risk of 
HAV infection (Cotter, 2003; Vong, 2005). The blood borne transmission is also responsible 
for number of outbreaks of hepatitis A (Peerlinck, 1998; Ridolfo, 2000).   
HAV Infection is hyperendemic in vast areas of the world, with approximately 1.5 million 
clinical cases per year (Fig. 5) (WHO, 2000). The worldwide distribution is uneven and is 
based on determinants such as socioeconomic conditions and geographic factors (Craig, 
2004; Wasley, 2006; Jacobsen, 2010). In developing countries, the incidence of disease in 
adults is relatively low because of exposure to the virus in childhood. Most adults in these 
areas show prevalence of antibodies against hepatitis A. In developed world endemicity is 
usually very low and clinical cases occur almost exclusively in adults (Feinstone, 1996; 
Marinho, 1997). The variable age distribution among hepatitis A patients in developing and 
developed countries is a consequence of differing standards of hygiene and sanitation. In 
many developing countries, improved hygiene standards and socio-economic conditions 
have led to a reduction in exposure to HAV in childhood and hence large non-immune 
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adult population in the community. This leads to a shift or transition from asymptomatic 
childhood infections to an increased incidence of symptomatic or clinical disease in adults 
(Hussain, 2006). The persistence of circulating HAV may lead to hepatitis A outbreaks in 
susceptible non-immune adult population (Arankalle, 2001; Hussain, 2006).  
 
 
Fig. 5. The global prevalence of hepatitis A virus infection based on presence of anti-bodies 
to hepatitis A virus i.e. anti-HAV. (Adapted from: Wasley, 2006)  
4. Molecular epidemiological characteristics 
Genetic heterogeneity of hepatitis A has been revealed by sequencing different genome 
regions, including VP3 carboxyl terminus, the VP1 amino terminus and the VP1/2A 
junction (Cohen, 1987; Arauz-Ruiz, 2001; Costa-Mattioli, 2002) (fig. 6). The VP3 C-terminal 
region is relatively conserved, the VP1 amino acid terminus presents an intermediate 
variability, while VP1/2A junction is more variable and is used to distinguish one strain 
from another (Costa-Mattioli, 2002). The genetic variability observed within the putative 
VP1/2A junction (168 nucleotides) initially defined seven (I-VII) genotypes (Khanna, 1992; 
Robertson, 1992; Ching, 2002). However, recently new classification of HAV has been done 
based on the complete sequences of the 900 nucleotides of VP1 region (Costa-Mattioli, 2002) 
(Fig. 6). The phylogenetic analyses of VP1 sequences identified six genotypes (I-VI) that 
differ among themselves 15-25%. Three isolated from humans (I-III) and three from a simian 
origin (IV-VI). The genotypes I, II and III were further subdivided into subgenotypes A and 
B, which differ in approximately 7.5% of base positions.  
The worldwide genotype distribution showed genotype I and III comprise the vast majority of 
human strains within the studied population (Fig. 7). Sub-genotype IA comprises the majority 
of the human strains studied and constitutes major virus population in North and South 
America, China, Japan, Russia and Thailand. The sub-genotype IB contains strains from 
Jordan, North Africa, Australia, Europe, Japan and South America. Most of the remaining 
human HAV strains segregate into genotype III that is further divided into two sub-genotypes, 
IIIA, and IIIB (Cohen, 1987; Jansen, 1990; Robertson, 1992). The sub-genotype IIIA have been 
subsequently identified in specimens collected from humans with hepatitis A in India, Sri 
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Lanka, Nepal, Malaysia, Sweden and the U.S.A [Khanna, 1992, Hussain, 2005]. The IIIB sub-
genotype is responsible for cases of HAV infection in Japan and Denmark.  
 
 
Fig. 6. The genomic organization of VP3 C-terminal, the VP1 amino acid terminal and 
VP1/2A junction region of hepatitis A virus. The complete sequence of the 900 nucleotides 
of the VP1 gene has been used for new classification of HAV. (Adapted from: Costa-
Mattioli, 2003) 
 
 
Fig. 7. Worldwide distribution of hepatitis A virus genotype(s) according to the VP3 
carboxyl terminus, the VP1 amino terminus and the VP1/P2A junction. (Adapted from: 
Wasley, 2006)   
In contrast, genotype II has rarely been reported worldwide. Recently, former genotype VII 
(SLF 88 isolate) has been reclassified within the genotype IIB (Costa-Mattioli, 2002; Lu, 2004) 
(Fig. 8 & 9). Similarly, sub-genotype II (CF-53/Berne isolate) has been defined as IIA in new 
HAV classification (Fig. 8 & 9).   
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Fig. 8. Neighbour joining phylogenetic tree of the VP1/P2A region using the two-parameter 
model of Kimura.  Genotypes and sub-genotypes are shown along with strains name. The 
strains (SLF-88 and 9F94) in bold has close genetic relationship and hence in latest 
nomenclature genotype VII has been reclassified in genotype IIB. (Adapted from: Costa-
Mattioli, 2002)   
The three simians genotypes were defined by unique nucleotide sequences from the P1 
regions of HAV strains. In addition, all simian HAVs have a distinct signature sequence at 
the VP3/VP1 junction which distinguishes these strains from human HAVs. 
 
 
Fig. 9. The phylogenetic tree based upon the nucleotide sequence of the structural proteins 
showing 3 different genotypes of human isolates and 2 simian isolates. (Adapted from: 
Costa-Mattioli, 2002)   
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4.1 Application of molecular technique in deciphering outbreaks 
Molecular techniques provide an important tool in decoding the epidemiological outbreaks 
of hepatitis A. These techniques have been successfully applied for the detection numerous 
HAV outbreaks linked to various sources such as clinical specimens and environmental 
samples such as faecally contaminated water, food (Hutin, 1999). There are several examples 
where molecular techniques such as RT-PCR and sequencing have been used effectively in 
outbreaks to definitely relate the source of infection (De Serres, 1999; Sanchez, 2002; 
Chironna, 2004; Arankalle, 2006; Tallon, 2008). The molecular epidemiological techniques 
also helped to report several outbreaks in major European cities among men who have sex 
with men (MSM) (Reintjes, 1999; Bell, 2001; Stene-Johansen, 2002) as well as in intravenous 
drug users (IVDUs) (Davidkin, 2007).  
4.2 Mode of evolution in HAV 
HAV replicates as complex dynamic mutant distributions and quasispecies. The 
evolutionary study of HAV over time also suggests continuous generation of variants or 
quasispecies that coexist in time and in different environment (Costa-Mattioli, 2003; 
Sanchez, 2003a). These findings suggest that beyond mutations and genetic recombination, 
HAV exploits variation strategy in dominance to promote and ensure its survival. Despite 
some degree of nucleotide heterogeneity at the capsid region of HAV, there is not an 
equivalent degree of amino acid variation (Aragonès, 2008; Pérez-Sautu, 2011). Severe 
structural constraints in the hepatitis A virus capsid prevent more extensive substitutions 
necessary for the emergence of new serotype, and hence existence of single serotype of 
human HAV (Bosch, 1998).  
5. Complications related to hepatitis A 
Fulminant hepatitis A is a rare complication, with reported incidence of 0.015 to 0.9% of 
overall cases worldwide (O’Gardy, 1993). The fulminant hepatitis A is occasional 
phenomenon during which more expensive necrosis of the liver occurs that follows 
impairment of hepatic synthetic processes, excretory functions and detoxifying 
mechanism. It occurs during the first 4-6 weeks of illness which is characterized by 
sudden onset of high fever, marked abdominal pain, vomiting and jaundice followed by 
development of hepatic encephalopathy associated with deep coma and seizures 
(O’Gardy, 1989; Takahashi, 1991). Mortality is highly correlated with increasing age, 
survival being rare over the age 45 years (Acharya, 1996). Clinical signs indicating liver 
failure include a rapid decrease in size of the liver, prolongation of the prothrombin time 
and decrease in the aminotransferase level as the bilirubin level continues to rise 
(Evangelos, 1989; Vento, 1998).  
5.1 Mortality rate  
The vast majority of hepatitis A patients make a full recovery and fatality rate is low. The 
estimated mortality rate is 0.1% for children less than 15 years old, 0.3% for adults ages 15 to 
39, and 2.1% for adults ages 40 and old (Hollinger, 1996; Debray, 1997). The acute HAV 
super infection with chronic liver disease is also associated with severity and high mortality 
(Keffe, 1995; Vento, 1998).  
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5.2 Treatment   
Specific treatment is not available for acute hepatitis A virus infection. As in most  
cases the infection is self-limiting and is followed by complete recovery without  
chronic sequelae, and no specific interventions are required. Patients with hepatic  
failure are highly recommended to transfer to centre capable of performing liver 
transplants.  
6. HAV control and prevention strategies   
HAV control and prevention strategies vary, depending on the country. The current WHO 
position paper (2000) includes specific positions for countries, depending on their HAV 
endemicity. In highly endemic countries, almost all persons are asymptomatically 
infected with HAV in childhood, which effectively prevents clinical hepatitis A in 
adolescents and adults. In these countries, large-scale vaccination program are not 
recommended. In countries of intermediate endemicity where a relatively large 
proportion of the adult population is susceptible to HAV, and where hepatitis A 
represents a significant public health burden, large-scale childhood vaccination may be 
considered as a supplement to health education and improved sanitation. In regions of 
low endemicity, vaccination against hepatitis A is indicated for individuals with 
increased risk of contracting the infection, such as travelers to areas of intermediate or 
high endemicity. Other high-risk persons include MSM and IVDUs communities (Francis, 
1984; Widell, 1983). Persons with underlying chronic liver disease from any cause, 
particularly if they are older than 45-50, are at increased risk of fulminant hepatitis A and 
should be immunized. Immunization of foodhandlers could prevent common source 
outbreaks of hepatitis, but the cost effectiveness of such a strategy is not known (Lemon 
and Shapiro, 1994).  
6.1 Vaccine and immune response 
HAV vaccines from various manufacturers are widely available in the market throughout 
the world. These vaccines have tremendous response with observed anti-antibody among 
children (91-100%) and young healthy adults (96%) which persists for up to 15-20 years after 
completion of vaccination schedule (WHO, 2000; Hammitt, 2008). 
7. Conclusion 
HAV remain an important cause of hepatitis outbreak and is a major public health problem 
worldwide especially in developing countries. It is mostly reported from poor sanitary and 
unhygienic surroundings, which emphasizes the need for improving the public health 
measures to prevent epidemics of hepatitis A. The changes in epidemiological pattern 
would increase the disease burden, may cause large community outbreaks and lead to 
increased healthcare cost. The emergence of new serotype is highly unlikely, although new 
variants can emerge if virus population is forced to severe immune selective pressure. Since 
hepatitis A exists as a single serotype and human is the only host, it is possible to eradicate 
by selective vaccination against individuals who are susceptible and sero-negative for HAV-
IgM. 
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